Patients with advanced non–small-cell lung cancer (NSCLC) who received immunotherapy, in particular immune checkpoint inhibitors in the first-line setting, lived longer than those who received chemotherapy, according to the findings of a meta-analysis and individual patient-level study recently published in JAMA Network Open.
“The findings of [the study] are well established over the last 3 to 5 years from multiple studies,” James Herman, MD, a medical oncologist at UPMC Hillman Cancer Center told Cancer Network. “It’s something we already knew.”
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.